“Screening for small-for-gestational age neonates at early third trimester in a high-risk population for preeclampsia”

Raquel Mula1*, Eva Meler1,2, Sandra García1, Gerard Albaigés1, Bernat Serra1, Elena Scazzocchio1,3 and Pilar Prats1

Abstract

Background: Strategies to improve prenatal detection of small-for-gestational age (SGA) neonates are necessary because its association with poorer perinatal outcome. This study evaluated, in pregnancies with first trimester high risk of early preeclampsia, the performance of a third trimester screening for SGA combining biophysical and biochemical markers.

Methods: This is a prospective longitudinal study on 378 singleton pregnancies identified at high risk of early preeclampsia according to a first trimester multiparametric algorithm with the cutoff corresponding to 15% false positive rate. This cohort included 50 cases that delivered SGA neonates with birthweight < 10th centile (13.2%) and 328 cases with normal birthweight (86.8%). At 27–30 weeks' gestation, maternal weight, blood pressure, estimated fetal weight, mean uterine artery pulsatility index and maternal biochemical markers (placental growth factor and soluble FMS-Like Tyrosine Kinase-1) were assessed. Different predictive models were created to evaluate their performance to predict SGA neonates.

Results: For a 15% FPR, a model that combines maternal characteristics, estimated fetal weight, mean uterine artery pulsatility index and placental growth factor achieved a detection rate (DR) of 56% with a negative predictive value of 92.2%. The area under receiver operating characteristic curve (AUC) was 0.79 (95% confidence interval (CI), 0.72–0.86). The DR of a model including maternal characteristics, estimated fetal weight and mean uterine artery pulsatility index was 54% (AUC, 0.77 (95% CI, 0.70–0.84)). The DR of a model that includes maternal characteristics and placental growth factor achieved a similar performance (DR 56%, AUC 0.75, 95% CI (0.67–0.83)).

Conclusions: The performance of screening for SGA neonates at early third trimester combining biophysical and biochemical markers in a high-risk population is poor. However, a high negative predictive value could help in reducing maternal anxiety, avoid iatrogenic interventions and propose a specific plan for higher risk patients.

Keywords: SGA neonates, high-risk patients, uterine artery Doppler, placental growth factor, prediction

Background

Growth-restricted fetuses are at increased risk of perinatal mortality and morbidity, but the risks can be reduced when the condition is prenatally detected. The traditional approach of identifying pregnancies at high risk of delivering low-weight neonates is measurement of symphysis–fundus height, with a low detection rate of affected fetuses, not higher than 30% [1]. A routine third-trimester ultrasound examination with measurement of fetal biometries is superior in identifying pregnancies at high risk of delivering low-weight neonates, with detection rates around 50% [2, 3] but the impact in improving perinatal outcome is unclear [4]. The last meta-analysis concluded that routine ultrasound in low-risk pregnancy identified 21% of growth-restricted fetuses [5]. The performance of screening for SGA at mid or late gestation is poor, with detection rates below 50% [6]. The role of maternal factors and placental markers in risk stratification is not clear. The aim of this study is to evaluate the performance of a third trimester screening combining maternal characteristics, estimated fetal weight and placental markers to detect SGA neonates at high risk of early preeclampsia.
risk or unselected population did not confer any benefit on the mother nor the baby in terms of perinatal mortality, preterm birth less than 37 weeks, caesarean section rates, and induction of labour rates [5].

The terms small-for-gestational age (SGA) and fetal growth restriction (FGR) have often been used interchangeably, but not all small neonates are growth-restricted, and not all growth-restricted neonates are small. Therefore, identification of high-risk neonates only by estimating fetal weight by ultrasound may be missing a significant proportion of cases with latent placental insufficiency. It seems reasonable to find new strategies to improve the detection of these neonates, especially when it is well known that SGA neonates have been associated with poorer perinatal outcome [6].

Maternal epidemiological characteristics such as maternal history of chronic hypertension and an impairment of placental function indirectly assessed by uterine Doppler measurement play a crucial role in the pathogenesis of placental-related pathology [7, 8]. Moreover, some studies have demonstrated changes in maternal plasma concentration of angiogenic and anti-angiogenic factors in these patients who will end up with preeclampsia (PE) and/or an SGA neonate [9]. Combined screening approaches at first trimester have been shown to be useful for the prediction of early-onset PE [10] but there is less evidence of its utility for late events, such as late PE, SGA neonates or adverse perinatal outcome, that are more prevalent. Since the screening of these entities is one of the major goals of current maternal-fetal medicine, new approaches to the prediction of late onset pregnancy complications have been proposed. Some studies have evaluated third trimester strategies incorporating maternal parameters and placental biomarkers and their improvement in the detection rate of SGA fetuses in the absence of preeclampsia [11–13]. Since most of these studies are based in general population and the two conditions share pathophysiological mechanisms, it is interesting to evaluate the risk of SGA neonates in a subgroup of patients identified at high risk of PE early in the pregnancy.

The aim of our study was to evaluate, in a subgroup of women classified as high risk of early preeclampsia using a first trimester multiparametric algorithm, the performance of a contingent third trimester screening for SGA combining maternal characteristics, uterine Doppler, fetal biometry, mean arterial pressure and biochemical markers.

Methods

Study design, setting and data source

Between 2014 and 2016, a prospective longitudinal study was undertaken at the Fetal Medicine Unit in the Hospital Universitari Dexeus, Barcelona (a tertiary university teaching hospital). The protocol was approved by the Dexeus Institutional Review Board for Human Investigation and the Ethics Committee (23/3/2013, reference number 20130313/17). Written informed consent was obtained from all patients and the reported investigations were carried out in accordance with the principles of the Declaration of Helsinki as revised in 2008. Data about pregnancy follow-up and outcome were collected from the electronic patient history.

Study population

All pregnancies were singletons and had complete follow-up in our center. Recorded patient characteristics included maternal age, method of conception (spontaneous or by assisted reproduction technique (ART)), cigarette smoking during pregnancy, maternal pathology such as history of chronic hypertension, pre-existing diabetes mellitus (DM), thrombophilia, kidney and autoimmune diseases, parity and obstetric history recording previous pregnancy with PE or SGA neonate.

Follow-up

Patients were enrolled at 8–9 weeks of pregnancy. Maternal history, height (cm) and weight (kg) were recorded and an ultrasound exploration was done concomitantly to date the pregnancy and confirm an ongoing singleton pregnancy at this moment. Crown-rump length (CRL) was measured in a neutral fetal position and the formula of Robinson and Fleming [14] was used to calculate gestational age. A blood sample was also obtained during this same visit for the determination of placental growth factor (PIGF) and biochemical parameters used for Down screening: free β-human chorionic gonadotropin (free β-hCG) and pregnancy-associated plasma protein A (PAPP-A).

Subsequently, first trimester assessment of the uterine artery Doppler at 11 + 0 to 13 + 6 weeks was performed transvaginally, and the mean uterine artery pulsatility index (UtA PI) was calculated as the average PI between right and left arteries [15]. Maternal weight and blood pressure (BP) were recorded at the time of the first trimester scan. Blood pressure was automatically measured in one arm (right or left), in a sitting position after 5-minute rest, according to the ISSHP recommendations [16]. Mean arterial pressure (MAP) was calculated as: diastolic BP + (systolic BP − diastolic BP)/3. Patients were classified as low or high risk of early PE using the algorithm previously published by Scaccozchietto et al. [17]. The former algorithm included maternal characteristics, maternal weight and height, medical history (chronic hypertension, pre-existing diabetes mellitus, thrombophilia, kidney disease and autoimmune disease), obstetric history (previous PE or SGA neonate), MAP and mean UtA PI. High-risk was defined as a cut-off
above 1/270, achieving a detection of 96% of cases for a false-positive rate (FPR) of 15%. The high-risk subgroup was followed-up in a specialized high-risk unit. At 19–22, 24–25 and 27–30 weeks of gestation, maternal weight and blood pressure was recorded and a transabdominal scan to measure fetal biometries, estimated fetal weight (EFW), mean UtA PI and umbilical artery (UA) pulsatility index was performed. Fetal biometries (biparietal diameter, head circumference, abdominal circumference and femur length) were measured according to the international guidelines [18]. EFW was calculated using Hadlock’s formula [19] and the centile was derived from local reference curves. If the EFW was below the 10th centile, fetal Doppler was performed: middle cerebral artery (MCA) PI, UA PI and cerebroplacental ratio (CPR). CPR was calculated as the ratio of MCA PI to UA PI. Ductus venosus (DV) PI was measured when previous Doppler parameters (UA, MCA, CPR) were altered. Maternal blood samples for PIGF and soluble FMS-Like Tyrosine Kinase-1 (sFlt-1) were collected at the time of the ultrasound (19–22, 24–25 and 27–30 weeks). SGA was defined as EFW below the 10th centile adjusted by gender and gestational age according to neonatal local standards [24].

Main outcome
SGA neonates were defined as birth weight less than the 10th centile adjusted by gender and gestational age according to neonatal local standards [24].

Statistical analysis
Mean ± standard deviation was reported for continuous variables and number and percentage were reported for categorical variables. Some variables transformed into z-score (absolute value minus divided by standard deviation) or MoMs (value divided by median of variable) according to our reference curves.

Chi-square test was used for the association between categorical variables with our primary outcome (SGA). Mann Whitney test or Student’s t-test was performed according to normality hypothesis. In parallel, a logistic regression was fitted to estimate the odds ratio (OR) and the 95% confidence interval (CI).

Finally, to adjust for confounding factors, a multivariable logistic model was analyzed. Receiver operating characteristics (ROC) curve and the area under the curve (AUC) according to sensibility and specificity were used to find the best model to estimate SGA.

All tests were bilateral with a significant level set to 5%. The statistical analysis was performed using IBM SPSS Statistics v22.0 software.

Results
Characteristics of the study population and perinatal outcome
The study population included 378 pregnancies with 1st trimester high risk screening of early preeclampsia out of 5876 women with singleton pregnancies screened at first trimester. The incidence of SGA among this cohort was 13.2% (n = 50). Our population was 94% Caucasian. Maternal biophysical characteristics, obstetric history and perinatal outcome are presented in Table 1. The incidence of global preeclampsia and gestational hypertension was 6% and 2.1%, respectively.

When we compared both groups, women with SGA neonates were more frequently nulliparous (78% vs 63.1%, p 0.04) and had lower body mass index (BMI) (23.1 vs 25.0 kg/m², p 0.004). The prevalence of smoking (8% vs 7.3%, p 0.776) and treatment with aspirin (14% vs 11%, p 0.576) during pregnancy was similar in both groups. The rate of induction of labor was higher in the SGA group (40% vs 24%, p 0.017) although the gestational age at induction was not statistically different (39.1 ± 1.33 vs 39.42 ± 1.62, p 0.226). The occurrence or preeclampsia (8% vs 5.8%, p 0.525), the rate of cesarean section (36% vs 32%, p 0.5), Apgar at 5’ (9.92 ± 0.27 vs 9.98 ± 0.64, p 0.995) and arterial pH (7.27 ± 0.06 vs 7.25 ± 0.08, p 0.181) were comparable between the two groups (Table 1).

First trimester screening
Interestingly, women with SGA neonates had significantly higher mean uterine artery Doppler pulsatility indexes (1.2 ± 0.3 vs. 1.4 ± 0.3, p < 0.001) and lower arterial pressure (85.8 ± 7.9 vs. 82.0 ± 7.1, p 0.002) at the time of first trimester screening. Moreover, the values PAPP-A (1 ± 0.5 vs. 0.8 ± 0.4, p 0.039) and PlGF (0.3 ± 0.2 vs. 0.2 ± 0.2, p0.002) at 8–10 weeks’ gestation were significantly lower (Table 2).

Second trimester uterine artery Doppler
Mean uterine artery pulsatility index at 19–22 weeks’ gestation was significantly increased in the group of pregnancies with SGA neonates (Table 2). Interestingly, we found that 48% (25/52) of women with pathological uterine Doppler at first trimester (mean UtA PI > 95th) maintained pathological uterine Doppler at 19–22 weeks’ gestation. Moreover, when we evaluated the group of women with SGA neonates, that percentage increased to 73.3% (11/15).
Third trimester screening

The mean gestational age at evaluation was 29 weeks (27-30.1). In the group of women with SGA neonates, the z-scores of EFW were significantly lower than in the group with normal birthweight (0.1 ± 1.0 vs. -0.7 ± 0.9, p < 0.001) and the mean UtA PI was significantly higher (1.2 ± 0.4 vs. 1.4 ± 0.5, p < 0.001). Contrarily, no significant differences in MAP were observed.

Moreover, MoM values of maternal serum PlGF were significantly lower (1.13 ± 0.9 vs. 0.70 ± 0.62, p < 0.001) and those of sFlt-1 as well as the sFlt-1/PlGF ratio significantly higher in the group of women who delivered SGA babies (0.9 ± 0.7 vs. 1.1 ± 0.8, p 0.037 and 1.8 ± 5.2 vs. 4.5 ± 6.8, p < 0.001, respectively) (Table 2).

Multivariate regression model at third trimester

A multivariate regression analysis demonstrated that the best prediction model at 27–30 weeks’ gestation was the combination of maternal characteristics, EFW (z-scores), mean UtA PI and PlGF with an AUC of 0.79 (95% CI, 0.72–0.86) (Fig. 1; Table 3). The detection rate (DR) for a 15% FPR was 56% with a negative predictive value (NPV) of 92.2%.

The DR of a model including maternal characteristics, EFW (z-scores) and mean UtA PI (MoM) was 54% (AUC of 0.77 95% CI, 0.70–0.84 (FPR 15%)). When we evaluated the addition of PlGF at 27–30 weeks’ gestation, we found that a model that includes maternal characteristics and PlGF achieved similar detection of SGA

### Table 1 Patients’ demographic characteristics and perinatal outcome in pregnancies with normal birthweight or small-for-gestational age neonates

| Characteristics                  | Normal birthweight (n = 328) | SGA (n = 50) | P      |
|----------------------------------|-----------------------------|-------------|--------|
| Maternal age (years)             | 35.5 ± 4.5                  | 34.7 ± 4.1  | 0.239  |
| Maternal weight (kg)             | 67.8 ± 13.1                 | 61.6 ± 11.4 | <0.001*|
| Maternal height (cm)             | 164.9 ± 6.1                 | 163.3 ± 6.7 | 0.089  |
| BMI (kg/m²)                      | 25.0 ± 4.7                  | 23.1 ± 3.7  | <0.001*|
| Smoking (%)                      | 7.3 (24)                    | 8 (4)       | 0.776  |
| Nulliparity (%)                  | 63.1 (207)                  | 78 (39)     | 0.040* |
| ART conception (%)               | 9.8 (32)                    | 4 (2)       | 0.286  |
| Pre-existing DM (%)              | 0.3 (1)                     | 0           | 0.696  |
| Chronic hypertension (%)         | 4.9 (16)                    | 4 (2)       | 0.786  |
| Kidney disease (%)               | 1.2 (4)                     | 0           | 0.432  |
| Autoimmune disease (%)           | 4.1 (13)                    | 2 (1)       | 0.704  |
| Thrombophilia (%)                | 1.5 (5)                     | 6 (3)       | 0.075  |
| Previous PE (%)                  | 4.6 (15)                    | 0           | 0.236  |
| Previous SGA (%)                 | 2.1 (7)                     | 6 (3)       | 0.133  |
| Treatment with AAS (%)           | 11.3 (37)                   | 14 (7)      | 0.576  |
| GA at delivery                   | 38.8 ± 1.8                  | 38.5 ± 1.8  | 0.259  |
| Induction of labour (%)          | 24 (79)                     | 40 (20)     | 0.017* |
| GA at induction                  | 39.42 ± 1.62                | 39.1 ± 1.33 | 0.226  |
| Cesarean delivery (%)            | 32 (105)                    | 36 (18)     | 0.5    |
| Birth weight (mean, g)           | 3200 ± 493                  | 2498 ± 352  | <0.001*|
| Neonatal feminine sex (%)        | 41.2 (135)                  | 32 (16)     | 0.218  |
| Arterial pH                      | 7.25 ± 0.08                 | 7.27 ± 0.06 | 0.181  |
| Apgar 5’                         | 9.98 ± 0.64                 | 9.92 ± 0.27 | 0.995  |
| S’ Apgar score < 7 (%)           | 0.6 (2)                     | 0           | 0.580  |
| Arterial pH < 7.15 (%)           | 10.5 (25)                   | 0           | 0.055  |
| Preeclampsia (%)                 | 5.8 (19)                    | 8 (4)       | 0.525  |
| Gestational Hypertension (%)     | 2.4 (8)                     | 0           | 0.604  |

Quantitative variables were expressed as mean ± SD
Categorical variables were expressed as % (n)
(*p < 0.05)
SGA Small-for-gestational age, BMI Body mass index, ART Assisted reproduction technique, DM Diabetes mellitus, PE Preeclampsia, GA Gestational age
neonates (DR of 56%, AUC of 0.75 95% CI, 0.67–272 0.83 (FPR 15%)) (Table 4).

**Discussion**

**Main findings**

This study shows that a model at early third trimester that combines maternal characteristics, EFW, uterine artery Doppler and PI GF achieves the detection of 56% of SGA neonates in a high-risk population of PE (FPR 15%), with a NPV of 92.2%. The performance of a model including maternal characteristics and PlGF is similar to a model including maternal characteristics and ultrasonic parameters (EFW and uterine artery Doppler).

**Comparison with previous studies**

Some studies in the literature have evaluated the addition of biochemical markers to ultrasound at third trimester to increase the prediction SGA neonates achieving modest results. Bakalis et al. showed that a screening combining maternal characteristics and biophysical and biochemical markers at 30–34 weeks detects 57% of SGA fetuses delivering ≥37 weeks [11]. Miranda et al. showed a model that, combining maternal characteristics, EFW, maternal and fetal Doppler and biochemical markers, achieved a detection of 61% of SGA cases (FPR 10%) [12]. Triunfo et al. evaluated fetuses with EFW > 10th centile at 32–36 weeks. They showed that a combination of sFlt-1/PIGF ratio and EFW resulted in a DR of 66% of SGA neonates (for a FPR of 20%) [13]. These models show slightly better performance than our study, performed on a previously selected high-risk population according to 1st trimester PE screening.

In our study, the risk of delivering SGA neonates was increased in nulliparous women and those with lower BMI. With regard to first trimester parameters, MAP, PAPP-A and PlGF were lower and mean UtA PI increased in women delivering SGA babies. The relationship of lower MAP with SGA may be attributed to its positive correlation with BMI [25]. About mean UtA PI, maternal characteristics and biochemical markers, several studies have demonstrated differences on pregnancies with SGA neonates at 11–13 weeks [26–28]. However, it is well known that first trimester screening of SGA neonates performs poorer than the screening for Preeclampsia [29, 30].

When focusing on early third trimester, we found that pregnancies with SGA neonates had lower EFW and PI GF and higher values of mean UtA PI, sFlt-1 and sFlt-1/PIGF. This is in agreement with several reports that have provided evidence that angiogenic factors are different in late events [11, 12, 31–34]. However, while both biochemical markers showed significantly different

---

**Table 2** First (11–13 weeks), second (19–22 weeks) and third (27–30 weeks) trimester evaluation

| First trimester evaluation | Normal birthweight (n = 328) | SGA (n = 50) | P     |
|----------------------------|-----------------------------|-------------|-------|
| - Mean uterine artery PI (MoM) | 1.2 ± 0.3 | 1.4 ± 0.3 | <0.001* |
| - MAP (mm Hg) | 85.8 ± 7.9 | 82.0 ± 7.1 | 0.002* |
| - PAPP-A (MoM) | 1 ± 0.5 | 0.8 ± 0.4 | 0.039* |
| - PI GF (MoM) | 0.3 ± 0.2 | 0.2 ± 0.2 | 0.002* |

| Second trimester evaluation | Normal birthweight (n = 328) | SGA (n = 50) | P     |
|----------------------------|-----------------------------|-------------|-------|
| - Mean uterine artery PI (MoM) | 1.2 ± 0.6 | 1.6 ± 0.5 | <0.001* |

| Third trimester evaluation | Normal birthweight (n = 328) | SGA (n = 50) | P     |
|----------------------------|-----------------------------|-------------|-------|
| - EFW (g) | 1399.3 ± 173.2 | 1244.5 ± 149.0 | <0.001* |
| - EFW (z-scores) | 0.1 ± 1.0 | -0.7 ± 0.9 | <0.001* |
| - Mean uterine artery PI (MoM) | 1.2 ± 0.4 | 1.4 ± 0.5 | <0.001* |
| - MAP (mmHg) | 81.9 ± 10.3 | 80.5 ± 9.9 | 0.372 |
| - PI GF (pg/mL) | 530.9 ± 423.1 | 328.4 ± 287.8 | <0.001* |
| - PI GF (MoM) | 1.13 ± 0.9 | 0.70 ± 0.62 | <0.001* |
| - sFlt-1 (pg/mL) | 1385.5 ± 1118.7 | 1692.5 ± 1206.7 | 0.037* |
| - sFlt-1 (MoM) | 0.9 ± 0.7 | 1.1 ± 0.8 | 0.037* |
| - sFlt-1/PI GF | 6.2 ± 17.1 | 14.7 ± 21.7 | <0.001* |
| - sFlt-1/PI GF (MoM) | 1.8 ± 5.2 | 4.5 ± 6.8 | <0.001* |

Quantitative variables were expressed as mean ± SD (*p < 0.05)

SGA Small-for-gestational age neonates, PI Pulsatility index, MoM Multiples of the median, MAP Mean arterial pressure, PAPP-A Pregnancy-associated plasma protein A, PI GF Placental growth factor, EFW Estimated fetal weight, sFlt-1 Soluble FMS-Like Tyrosine Kinase-1
concentrations between SGA and normally growing fetuses, PlGF was the only biochemical marker included in the model. This is consistent with previous studies that have demonstrated that decreased levels of PlGF are predictive of histological signs of underperfusion found in most pregnancies associated with FGR [35, 36]. Other studies haven’t found differences in sFlt-1 levels in pregnancies complicated with SGA without PE, suggesting that it is a more specific biomarker for maternal endothelial impairment associated to this latter condition [9, 37]. Consistent with these findings, Gaccioli et al. evaluated the effectiveness of the combination of fetal biometries and sFlt-1/PlGF ratio at 28 and 36 weeks in a low-risk population. They found that, at 28 weeks, PlGF and sFlt-1/PlGF were equally predictive for preterm SGA while sFlt-1 was a weaker predictor. This latter showed a sensitivity of 50% compared to 76.9% of PlGF and 73.1% of sFlt/PlGF respectively [38].

Cases of early growth restriction are specially associated with placental insufficiency and the associated changes in serum metabolites, which are linked to the severity of the disease. Herráiz et al. found that the sFlt1/PlGF ratio rose 4 weeks before the delivery of FGR fetuses, regardless of the presence of PE [39]. The low incidence of preterm SGA babies in our series (6 cases) could have blinded the utility of these parameters.

The evaluation of PlGF is an objective and feasible parameter that could be measured at bedside, avoiding problems related to operator depending ultrasound skills. Therefore, it could be a better option to detect high risk pregnancies in some settings where the possibility of performing a third trimester ultrasound is not available. Moreover, it could be part of a contingent

---

**Table 3** Variables included in the third trimester predictive model

| Variable                | OR (CI 95%)         |
|-------------------------|---------------------|
| Maternal age            | 0.98 (0.90–1.07)    |
| Maternal weight         | 0.96 (0.92–0.99)    |
| EFW (z-scores)          | 0.55 (0.31–0.82)    |
| PlGF (log MoM)          | 0.59 (0.39–0.89)    |
| Mean uterine artery PI (MoM) | 3.04 (1.33–6.94) |

OR Odds ratio, CI Confidence interval, EFW Estimated fetal weight, PlGF Placental growth factor, log MoM Multiples of the median of the log10 for PlGF, MoM Multiples of the median, PI Pulsatility index
screening: Evaluating PI GF as a first step and performing ultrasound only if it is altered. Some studies have proposed protocols that evaluate the risk of growth restriction at second trimester and propose a specific follow-up based on the results of this screening [40–42]. Tristuno et al. performed a third trimester scan in 50% of the population based on a second trimester screening achieving equivalent results to the strategy of performing a third trimester scan to the whole population (AUC 0.89 vs. 0.92) [40]. Poon et al. used a second trimester screening with biophysical (biometries, mean UtA PI) and biochemical (PI GF and alfa-fetoprotein (AFP)) markers to decide when to perform the third trimester scan. According to their results, 11% of the population required an ultrasound at 32 weeks and 44% at 36 weeks, with the objective to predict 80% of cases of SGA < 5th centile [41]. In a similar line, Lesmes et al. performed a second trimester screening combining fetal biometries and biochemical markers (PI GF, sFlt1, PAPP-A, free b-HCG and AFP), estimating that 11% and 46% of the population needed respectively to be reassessed at 32 and 36 weeks, to achieve an 80% detection of SGA < 5th centile [42].

We have no doubt that the way to detect the majority of pregnancies that will end with the birth of a SGA neonate, or at least to discard this possibility, goes through a combined model. The negative predictive value of our model (92.2%) is a remarkable aspect of the study. A model including PI GF may be useful as an additional tool for risk stratification classifying pregnancies as low or high risk of delivering late SGA neonates and, consequently, we may expect to rule out lower risk patients in order to avoid iatrogenic interventions and propose a specific plan for higher risk patients.

Strengths and limitations

One strength of the study is that we evaluated a high-risk population of placental disease. We did not find studies that focus on such high-risk patients in which the prevalence of SGA neonates is expected to be higher. Another important issue is that the follow-up of the patients was strict and integrally made in our center and all our professionals had been trained to measure uterine Doppler PI and blood pressure.

On the other side, the limitations of our study are: first, that the population is very small with only 50 cases of SGA neonates. We believe that we would obtain better results in a larger population. Secondly, in our study the patients were evaluated by ultrasound at the beginning of the third trimester and this fact may decrease the effectivity of the model. It would be interesting to evaluate the model performing the third trimester assessment at 36 weeks. However, this strategy would have the disadvantage of limiting management alternatives. We do not consider prophylactic use of Aspirin a limitation of the study because it was not different between both groups. Indeed, it reflects the real clinical practice after the results of ASPRE trial [43]. According to this study, in high-risk women for PE by means first trimester screening, the use of aspirin reduces the incidence of preterm and early SGA by 20% and 40%, respectively. However, most cases of late SGA are not preventable.

Conclusions

In conclusion, the performance of screening for SGA at early third trimester combining maternal characteristics, mean UtA PI, fetal biometry, MAP and biochemical markers in a high-risk population is poor. However, the high NPV may help to reduce maternal anxiety in this specific group of women at high risk of developing PE, change the policy of performing third trimester ultrasound in 100% of population and avoid iatrogenic interventions. Future studies are necessary to evaluate the performance of third trimester combined screening models, define specific protocols for high-risk pregnancies and evaluate if these protocols could reduce perinatal morbidity and mortality.

Abbreviations

SGA: Small-for-gestational age neonates; AUC: Area under receiver-operating characteristic curve; DR: Detection rate; FPR: False-positive rate; EFW: Estimated fetal weight; UtA PI: Uterine artery Doppler pulsatility index; PI GF: Placental growth factor; log MoM: Multiples of the median of the log10 for PI GF; MoM: Multiples of the median; PlGF: Placental growth factor; free β-HCG: Free β-human chorionic gonadotropin; PAPP-A: Pregnancy-associated plasma protein A; Ut A PI: Uterine artery pulsatility index; BP: Blood pressure; MAP: Mean arterial pressure; FPR: False positive rate; EFW: Estimated fetal weight; UA: Umbilical artery; MCA: Middle cerebral artery; CPR: Cerebroplacental ratio; NV: Ductus venous; sFlt-1: Soluble FMS-Like Tyrosine Kinase-1; MoM: Multiples of the median; OR: Odds ratio; CI: Confidence interval; ROC: Receiver operating characteristics curve; AUC: Area under receiver–operating characteristics curve; BMI: Body mass index; DR: Detection rate; NPV: Negative predictive value; AFP: Alpha-fetoprotein; GA: Multiples of the median of the log10 for PI GF.
Acknowledgements

The authors thank Carme Comas, PhD, and Marta Ricart, MD, for following-up the patients and reviewing medical records. Reagents for PIGF and sFlt-1 determination were provided by Roche Diagnostics.

Authors' contributions

ES, RM, EV and PP designed the trial. ES, EM and RM recruited patients and followed-up in a specialized high-risk unit. SG performed the statistical analysis. RM, EM, GA, BS and PP interpreted the data and critically reviewed the article. All authors have read and approved the manuscript.

Funding

No funding was received for the design of the study, statistical analysis, interpretation of data, or the writing of the manuscript.

Ethics approval and consent to participate

The protocol was approved by the Dexeus Institutional Review Board for Human Investigation and the Ethics Committee (23/3/2013, reference number 20130313/07). Written informed consent was obtained from all patients and the reported investigations were carried out in accordance with the principles of the Declaration of Helsinki as revised in 2008.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used during the present study are available from the corresponding author on reasonable request.

Competing interests

None of the other authors have a conflict of interest to report.

Author details

1Department of Obstetrics, Gynecology and Reproduction, Hospital Universitari Dexeus, Dexeus Mujer, Barcelona, Spain. 2Hospital Clinic de Barcelona, Institut Clinic de Ginecologia Obstetricia i Neonatologia, Barcelona, Spain. 3Institut Catala de la Salut, Atenció a la Salut Sexual i Reproductiva (ASSIR) de Barcelona, Barcelona, Spain.

Received: 10 March 2020 Accepted: 11 August 2020
Published online: 25 September 2020

References

1. Pay AS, Wilk J, Backe B, Jacobsson B, Strandell A, Klovning A. Symphysis-fundus height measurement to predict small-for-gestational-age status at birth: a systematic review. BMC Pregnancy Childbirth. 2015;15:12.
2. De Reu PA, Smits LJ, Oosterbaan HP, Nijhuis JG. Value of a single early third trimester fetal biometry for the prediction of birth weight deviations in a low risk population. J Perinat Med. 2008;36(4):324–9.
3. David C, Tagliavini G, Pilu G, Rudenholz A, Bovicelli L. Receiver-operator characteristic curves for the ultrasonographic prediction of small-for-gestational-age fetuses in low-risk pregnancies. Am J Obstet Gynecol. 1996;174:1037-42.
4. Sovic U, White JR, Dacey A, Pasupathy D, Smith GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (PO) study: a prospective cohort study. Lancet. 2015;386:2089–97.
5. Bricker L, Medley N, Pratt JJ. Routine ultrasound in late pregnancy (after 24 weeks' gestation) (Review). Cochrane Database Syst Rev. 2015 Jun;29(6):.
6. Figueras F, Fisac H, Eimer B, Iroa A, Figueras J, Puerto B, Gratacos E. Small-for-gestational-age fetuses with normal umbilical artery Doppler have suboptimal perinatal and neurodevelopmental outcome. Eur J Obstet Gynecol Reprod Biol. 2008;136:34–8.
7. Bartch E, Medcalf KE, Park AL, Ray JG. High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BJM. 2016;353:i1753.
8. Seed PT, Chappell LC, Black MA, Poppe KH, Hwang YC, Kasabov N, McCowan L, Shennan AH, Wu SH, Poston L, North RA. Prediction of preeclampsia and delivery of small for gestational age babies based on a combination of clinical risk factors in high-risk women. Hypertens Pregnancy. 2011;30(1):58–73.
9. Roberto Romero JX, Nien J, Espinoza D, Todor W, Fu H, Chung JP, Kusanovic F, Gotsch O, Erez SMazaki-Tovi, Gomez R, Edwin S, Chawwareponga T, Levine RJ, S, Ananth Karumanchi. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008 Jan;21(1):9–23.
10. O’Gorman N, Wright D, Syngelakis A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol. 2016;214(1):103.e1-103.e12.
11. Bakalis S, Peeva G, Gonzalez R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30–34 weeks. Ultrasound Obstet Gynecol. 2015;46:446–51.
12. Miranda J, Rodriguez-Lopez M, Triunfo S, Saitane M, Kouru H, Parra Saavedra M, Crovetto F, Figueras F, Crispi F, Gratacos E. Prediction of fetal growth restriction using estimated fetal weight vs a combined screening model in the third trimester. Ultrasound Obstet Gynecol. 2017;50:603–11.
13. Triunfo S, Parra-Saavedra M, Rodriguez-Sureda V, Crovetto F, Dominguez C, Gratacos E, Figueras F. Angiogenic Factors and Doppler Evaluation in Normally Growing Fetuses at Routine Third-Trimester Scan: Prediction of Subsequent Low Birth Weight. Fetal Diagn Ther. 2016;40(1):113–20.
14. Robinson HP, Fleming JE. A critical evaluation of sonar ‘crown-rump-length’ measurements. Br J Obstet Gynaecol. 1975;82(9):702–10.
15. Gómez O, Figueras F, Fernández S, Bennasar M, Martinez JM, Puerto B, Gratacos E. Reference range for uterine artery mean pulsatility index at 11–41 weeks of gestation. Ultrasound Obstet Gynecol. 2008;32(2):128–32.
16. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:IX-XV.
17. Scaccozchio E, Figueras F, Crispi F, Meler E, Mascoll N, Mula R, Gratacos E. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol. 2013;208(3):203.e1-203.e10.
18. Salomon LJ, Alfveficius B, Berghella V, Bicalho C, Hernandez-Anderade E, Johnson SL, Kalache K, Leung KY, Malinger G, Munoz H, Perfumo F, Toi A, Lee W. ISUOG Clinical Standards Committee. Practice guidelines for performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol. 2011;37(1):116–26.
19. Hadlock FP, Harrisk RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements—a prospective study. Am J Obstet Gynecol. 1985;153:333–42.
20. Arduini D, Rizzo G. Normal values of Pulsatility Index from fetal vessels: a cross-sectional study on 1565 healthy fetuses. J Perinat Med. 1990;18(3):165–72.
21. Baschat AA, Gembrukh U. The cerebroplacental Doppler ratio revisited. Ultrasound Obstet Gynecol. 2003 Feb;21(2):124–7.
22. Hecker K, Campbell S, Snijders R, Nicolaides K. Reference ranges for fetal venous and aortic/ventricular blood flow parameters. Ultrasound Obstet Gynecol. 1994 Sep;4(5):1381–90.
23. Figueras F, Gratacos E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36(2):86–98.
24. Departament de Salut. Generalitat de Catalunya. Corbes de referència de pes, perímetre cranial i longitud en néixer de nens d’embarassos únics, de besses i de trigèmens a Catalunya. 2008.
25. Shahabi J, Ganayyarghi M, Shariati Z, Khaleghi A, Hedayat A, Givi M, Vadegefar G. The association of anthropometric indices and cardiac function in healthy adults. ARYA Atheroscler. 2019. Jan;15(1):19–13.
26. Sung KI, Roa JA, Ech KL, Kim E. Maternal serum placental growth factor and pregnancy associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational age infants: A prospective observational study. Obstet Gynecol. 2017. Mar;120(2):154–62.
27. Sibich C, Frycz J, Frolich S, Schmidt M, Klininger A, Kimmig R, Schmidt B, Gehlhaus A. Impact of maternal serum levels of Visfatin, APP, PAPP-A, sFlt-1 and PIGF at 11–13 weeks’ gestation on small for gestational age births. J Matern Fetal Neonatal Med. 2017 Mar;30(6):629–34.
28. Sotiadiadis A, Figueras F, Eleftheriades M, Papaioannou GK, Chorozoglou G, Dinas K, Papantonou N. First-trimester and combined first- and second-
trimester prediction of small-for-gestational age and late fetal growth restriction. Ultrasound Obstet Gynecol. 2019 Jan;53(1):55–61.

29. Seravalli V, Block-Abraham DM, Turan OM, Doyle LE, Kopelman JN, Atlas RO, Jenkins CB, Blitzer MG, Baschat AA. First-trimester prediction of small-for-gestational age neonates incorporating fetal Doppler parameters and maternal characteristics. Am J Obstet Gynecol. 2014 Sep;211(3):261.e1-8.

30. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11–13 weeks. Fetal Diagn Ther. 2013;33(1):16–27.

31. Schoofs K, Grittner U, Engels T, Pape J, Henrich W, Verloehren S. The importance of repeated measurements of the sFlt-1/PIGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med. 2014 Jan;42(1):61–8.

32. Birdir C, Droste L, Fox L, Frank M, Fryze J, Enekewa A, Kinninger A, Kimmig R, Schmidt B, Gellhaus A. Predictive value of sFlt-1, PIGF, sFlt-1/PIGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy. Pregnancy Hypertens. 2018 Apr;12:1-8.

33. Kwiatkowski S, Bednarek-Jędrzejek M, Kołodziej J, Tousty P, Kwiatkowska E, Cymbaluk A, Zeepeka R, Chudecka-Gladz A, Dołęgoszka B, Torbá B, sFlt-1/PIGF and Doppler ultrasound parameters in SGA pregnancies with confirmed neonatal birth weight below 10th percentile. Pregnancy Hypertens. 2018;14:79–85. https://doi.org/10.1016/j.preghy.2018.08.448 (Epub 2018 Aug 17).

34. Anca Ciobanu MD, Angeliki Rouvali MD, Argyro Syngelaki PhD, Ranjit Akolekar MD, Kypros H, Nicolaides MD. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35–37 weeks’ gestation. Am J Obstet Gynecol. 2019;220(5):486.e1-486.e11.

35. Benton Samantha J, McComb LM, Heazell Alexander EP, Grynspan D, Hutcheon JA, Senger C, Harding JE, Yockell-Leliiev Julien, Hu Xuanyi, Chappell Lucy C, Griffin MJ, Shennan AH, Magee LA, Gruslin Andree, von Dadelszen Peter. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.

36. Triunfo S, Lobmaier S, Parra-Saavedra M, Crovetto F, Peguero A, Nadal A, Gratacos E, Figueras F. Angiogenic factors at diagnosis of late-onset small-for-gestational-age and histological placental underperfusion. Placenta. 2014 Jun;35(6):398-403.

37. MacDonald Teresa M, Tran C, Kaitu-Lino Tuhevaha J, Brennecke SP, Hiscock RJ, Hui Lisa, Dale KM, Middleton AL, Cannon Ping, Walker Susan P, Tung Stephen. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. BMC Pregnancy Childbirth. 2018;18:354.

38. Francesca Gaccioli U, Sovio E, Cook M, Hund DS, Charnock-Jones, Gordon CS, Smith P. Screening for fetal growth restriction using ultrasound and the sFlt1/PIGF ratio in nulliparous women: a prospective cohort study. Lancet Child Adolesc Health. 2018 Aug;2(8):569–81.

39. Herraiz I, Quezada MS, Rodriguez-Calvo J, Gomez-Montes E, Villalain C, Galindo A. Longitudinal change of sFlt-1/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction. Ultrasound Obstet Gynecol. 2018;52:361–8.

40. Triunfo S, Crovetto F, Scaccizocchio E, Parra-Saavedra M, Gratacós E, Figueras F. Contingent versus routine third-trimester screening for late fetal growth restriction. Ultrasound Obstet Gynecol. 2016;47:81–8.

41. Poon C, Lesmes C, Gallo DM, Akolekar R, and K. H. Nicolaides. Prediction of small-for-gestational age neonates: screening by biophysical and biochemical markers at 19–24 weeks. Ultrasound Obstet Gynecol. 2015;46:437–45.

42. Lesmes C, Gallo DM, Gonzalez R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19–24 weeks. Ultrasound Obstet Gynecol. 2015;46:341–9.

43. Tan MY, Poon LC, Rolnik DL, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina ES, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright D, Nicolaides KH. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. Ultrasound Obstet Gynecol. 2018;52(1):52–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.